Allylescaline, known chemically as 4-allyloxy-3,5-dimethoxyphenethylamine, is a relatively lesser-known psychedelic substance. Structurally, it bears a close resemblance to mescaline. This unique compound was first synthesized by Otakar Leminger in 1972.
Notably, Alexander Shulgin later synthesized allylescaline and included a detailed description of its properties in his book PiHKAL (Phenethylamines I Have Known and Loved). The recommended dosage range for allylescaline falls within 20 to 35 mg when consumed orally, with the effects typically lasting for approximately 8 to 12 hours.
Allylescaline is renowned for inducing entactogenic warmth, entheogenic experiences, and a sense of flowing energy. Despite its intriguing effects, there is a limited amount of available data concerning its pharmacological properties, metabolism, and toxicity.

CAS Number39201-75-7 
3D model (JSmol)Interactive image
PubChemCID4471946971669102 hydrochloride
CompTox Dashboard(EPA)DTXSID80660348
Chemical formulaC13H19NO3
Molar mass237.299 g·mol−1

Legal status

Allylescaline is illegal in Sweden as of January 2016.


1. What is Allylescaline?

  • Allylescaline is a lesser-known psychedelic compound with structural similarities to mescaline, renowned for its unique psychoactive effects.

2. Who first synthesized Allylescaline?

  • Allylescaline was originally synthesized by Otakar Leminger in 1972, and Alexander Shulgin further described its properties in his book PiHKAL (Phenethylamines I Have Known and Loved).

3. How is Allylescaline typically consumed?

  • Allylescaline is commonly taken orally, and the recommended dosage range, as per Shulgin’s notes, is typically between 20 and 35 mg.

4. What are the effects and duration of Allylescaline?

  • Allylescaline is known to induce entactogenic warmth, entheogenic experiences, and a sense of flowing energy. The effects typically last for about 8 to 12 hours, although individual experiences may vary.

5. Is Allylescaline legal?

  • The legal status of Allylescaline varies by country and jurisdiction. It may be controlled in some regions, while in others, it might be unregulated or fall into a legal gray area. It’s essential to understand the specific regulations in your area.

6. Are there any potential risks associated with Allylescaline use?

  • As with any psychedelic substance, using Allylescaline carries potential risks, including psychological distress and adverse effects. It is important to consider set and setting when using this compound.

7. Can Allylescaline be used for therapeutic purposes?

  • There is limited research on the therapeutic potential of Allylescaline, and it is not approved for medical or therapeutic use. Other psychedelics, like psilocybin and MDMA, have been more extensively studied for therapeutic applications.

8. Is Allylescaline addictive?

  • The addictive potential of Allylescaline is not well understood, but it is generally considered to have a lower risk of physical dependence compared to substances like opioids or stimulants. Psychological dependence can still occur.

9. Where can I find more information about Allylescaline?

  • Given the evolving legal and scientific landscape surrounding Allylescaline, it’s important to consult reliable sources of scientific literature and seek advice from healthcare professionals. Staying informed and making well-informed decisions is crucial when considering the use of this substance.


  1. In 1972, Otakar Leminger contributed to the scientific understanding of compounds like Allylescaline in his research titled “The Chemistry of Alkoxylated Phenethylamines – Part 2,” published in the journal Chemický Průmysl.
  2. Detailed information about Allylescaline can be found in the entry dedicated to it in Alexander Shulgin’s PiHKAL (Phenethylamines I Have Known and Loved).
  3. In November 2015, the Swedish public health agency, Folkhälsomyndigheten, made an announcement regarding the classification of substances, stating that 31 new substances could be classified as controlled substances or hazardous materials.

Leave a Comment

Your email address will not be published. Required fields are marked *